Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $113.4 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 36.42% year-over-year to $113.4 million in Q1 2026; TTM through Mar 2026 was $486.8 million, a 50.19% decrease from a year earlier, with the FY2025 full-year figure at $551.7 million, down 48.29% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $113.4 million, up from $94.7 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for NTLA reached as high as $321.6 million in Q4 2024 and fell as low as $93.7 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $192.2 million across 5 years, with a median of $199.7 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments soared 181.24% in 2023 and tumbled 70.55% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $210.2 million in 2022, then declined by 6.17% to $197.2 million in 2023, then soared by 63.08% to $321.6 million in 2024, then tumbled by 70.55% to $94.7 million in 2025, then gained by 19.69% to $113.4 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $113.4 million in Q1 2026, $94.7 million in Q4 2025, and $115.9 million in Q3 2025.